{"prompt": "['Amended Clinical Trial Protocol No. 05', '15-Dec-2021', 'GZ402673-EFC13429 - alemtuzumab', 'Version number: 1', '17 APPENDICES', 'Property of the Sanofi Group - strictly confidential', 'Page 102', 'VV-CLIN-0254406: 5.0']['Amended Clinical Trial Protocol No. 05', '15-Dec-2021', 'GZ402673-EFC13429 - alemtuzumab', 'Version number: 1', 'Appendix A', 'Guidance on contraceptive methods and collection of pregnancy', 'information', 'Women Of Child Bearing Potential', 'A woman is considered of reproductive potential (WOCBP), ie, fertile, following menarche and', 'until becoming postmenopausal unless permanently sterile. Permanent sterilization methods', 'include hysterectomy, bilateral salpingectomy and bilateral oophorectomy.', 'Women of Child Bearing Potential must use one of the highly effective methods from the lists', 'below:', 'Highly Effective Contraceptive Methods That Are User Dependent', 'Failure rate of <1% per year when used consistently and correctly', 'Combined (estrogen- and progestogen-containing ) hormonal contraception associated', 'with inhibition of ovulation:', '- Oral,', '- Intravaginal,', '- Transdermal.', 'Progestogen-only hormone contraception associated with inhibition of ovulation:', '- Oral,', '- Injectable.', 'Highly Effective Methods That Are User Independent', 'Implantable progestogen-only hormone contraception associated with inhibition of', 'ovulation.', 'Intrauterine device (IUD).', 'Intrauterine hormone-releasing system (IUS).', 'Sexual abstinence', 'Sexual abstinence is considered a highly effective method only if defined as refraining from', 'heterosexual intercourse during the entire period of risk associated with the study drug. The', 'reliability of sexual abstinence needs to be evaluated in relation to the duration of the study and', 'the preferred and usual lifestyle of the subject.', 'NOTE:', 'a.', 'Typical use failure rates may differ from those when used consistently and correctly. Use should be consistent with local regulations', 'regarding the use of contraceptive methods for subjects participating in clinical studies.', 'Property of the Sanofi Group - strictly confidential', 'Page 103', 'VV-CLIN-0254406: 5.0']['Amended Clinical Trial Protocol No. 05', '15-Dec-2021', 'GZ402673-EFC13429 - alemtuzumab', 'Version number: 1', 'COLLECTION OF PREGNANCY INFORMATION', 'Female subjects who become pregnant', 'The Investigator will collect pregnancy information on any female subject, who becomes', 'pregnant while participating in this study.', 'Information will be recorded on the appropriate form and submitted to the Sponsor within', \"24 hours of learning of a participant's pregnancy.\", 'Participant will be followed to determine the outcome of the pregnancy. The Investigator', 'will collect follow-up information on participant and neonate, which will be forwarded to', 'the Sponsor. Generally, follow-up will not be required for longer than 6 to 8 weeks beyond', 'the estimated delivery date.', 'Any termination of pregnancy will be reported, regardless of fetal status (presence or', 'absence of anomalies) or indication for procedure.', 'In this study pregnancy is considered to be an AESI and will be reported as such, any', 'pregnancy complication or elective termination of a pregnancy will be reported as an AE', 'or SAE.', 'A spontaneous abortion is always considered to be an SAE and will be reported as such.', 'Any SAE occurring as a result of a poststudy pregnancy which is considered reasonably', 'related to the study treatment by the Investigator, will be reported to the Sponsor as', 'described in Section 10.4.1.3. While the Investigator is not obligated to actively seek this', 'information in former study subjects, he or she may learn of an SAE through spontaneous', 'reporting.', 'Male subjects with partners of reproductive potential who become pregnant', 'The Investigator will attempt to collect pregnancy information on any female partner of a', 'male study subject who becomes pregnant while participating in this study. This applies', 'only to subjects who receive study treatment.', 'After obtaining the necessary signed informed consent from the pregnant female partner', 'directly, the Investigator will record pregnancy information on the appropriate form and', \"submit it to the Sponsor within 24 hours of learning of the partner's pregnancy.\", 'Partner will also be followed to determine the outcome of the pregnancy. Information on', 'the status of the mother and child will be forwarded to the Sponsor.', 'Generally, follow-up will be no longer than 6 to 8 weeks following the estimated delivery', 'date. Any termination of the pregnancy will be reported regardless of fetal status (presence', 'or absence of anomalies) or indication for procedure.', 'Property of the Sanofi Group - strictly confidential', 'Page 104', 'VV-CLIN-0254406: 5.0']\n\n###\n\n", "completion": "END"}